

MEDXtractor
Corp.

“The Multibillion Dollar Possibilities When Psychedelics Meet Artificial Intelligence”



Did you know that by age 40, approximately 50% of Canadians will have, or have had, a mental illness? *

A fundamental problem is that misdiagnosis rates for mental afflictions can exceed 70%**; with misdiagnosis potentially leading to improper drug prescriptions that can actually worsen the actual affliction. Two major factors behind this problem are 1. human diagnostic bias, and 2. a lack of coherent, validated data. Artificial Intelligence ("AI") (also referred to as "Machine Learning") can mitigate the human bias but the lack of underlying coherent, validated data continues to plague efforts to reduce misdiagnosis/misprescription rates. An AI-based platform being developed by a Calgary-based public tech Company thinks it has a solution.

The SHAMAN platform created by **MedXtractor Corp.** ([CSE: MXT](#), [OTC: MXTTF, Forum](#)) is touted as a machine-learning-based tool designed to help reduce misdiagnosis while increasing the efficiency of the healthcare system generally. SHAMAN is designed to become ever-more-intelligent as its validated database grows. Adding to the potential is the revolutionary "mHealth" movement that is projected to fundamentally alter worldwide healthcare. When MedXtractor made SHAMAN's [presence in the public markets known](#) this past New Year's Eve, the SHAMAN platform was hailed as a means to use AI to predict the potential of nature-based psychedelics in mental health treatment. This is not the extent of the platform's capabilities, but the potential for its capabilities related to mental afflictions and associated prescriptions seemed like a perfect marriage.


How does it work?

SHAMAN is like Google, but different. Where Google accesses massive amounts of data, the data is not validated and this naturally limits the utility of the search results - meaning Google results represent more of a "beginning point" for what the user is trying to achieve. SHAMAN's design relies on only validated, correlated data that is directly related to the target application (such as mental health), with results representing something much closer to a probable "end point". SHAMAN's data records specify a large set of factual correlated data and it's these validated records that are used to generate the high-probability "end points". If Google is a shotgun, SHAMAN is a high-powered rifle. Importantly, SHAMAN's predictive ability does not need to know "who" you are, instead relying on "why and what" you are. This means validated records gathered from participating members can be rendered anonymous so there is no risk of a data record being connected to the member who provided the record. This is privacy in the extreme. The more validated records added, the higher the resolution of the predictive opinions. SHAMAN is designed to grow forever, getting "smarter" over time.

While SHAMAN will contain information that can be used to form predictions on a large variety of afflictions, the initial validation phase will focus on mental health afflictions and the treatment potential of psychedelic compounds thereto. Many types of data can be added to a validated record; for example EEG data, EKG data, and bloodwork - all of which may increase the record quality and the probability of more accurate predictions.

The "mHealth" factor:

mHealth is a burgeoning global phenomenon expected to revolutionize healthcare.



As you can see, the global mHealth market size is projected to grow from \$53 billion (USD) in 2021 to \$166 billion in 2028. Note that the "wearables" sector, including the devices shown below, is quite small compared to the "applications" sector where SHAMAN resides. Some mHealth devices are below:



(Image via MedXtractor Corp.)

While the above devices represent mHealth initiatives, they do not address the underlying need for validated, coherent data. As such they are starting "from the top down". SHAMAN, on the other hand, is starting from the ground up by designing, accumulating and correlating validated data.

With SHAMAN well positioned to benefit from this worldwide growth trend, let's dig a little deeper into MXT and its market potential

Who's running the show?

CEO Durward is a multi-patented, published inventor with significant experience in the conceptualization, development, and commercialization of large-scale, pattern recognition and image analysis databases and associated interpretational software. Another member of the MXT Board of Directors, Dušan Kuzma MBA, MSc., holds a graduate degree in organic chemistry with more than 10 years of experience in R&D, product development, and product commercialization. Additional "firepower" is contracted on an "as-needed" basis and this allows MXT to tightly control costs - something MXT is known for. Small teams can be more tightly focused and a more efficient use of capital. Importantly, as at this date, insiders control over 40% of the outstanding shares.

When will it be available?

According to CEO Durward, the SHAMAN reference database is being built in phases with the first phase being open for participation on February 22, 2021. He says it is expected to take until the latter part of 2021 to accumulate a critical mass of validated records and finalize the machine-learning algorithm testing before opening to the public prior to year end, 2021.

Where is the money coming from?

The Company generates cash from the manufacture/sale of craft-scale bio-extractors (internally-developed and it owns the patents) that are used to extract compounds from a variety of botanical materials - think craft-scale medical cannabis. Most of the sales are international with installations in more than ten countries worldwide. Despite the depressing effects of COVID-19, in January 2021, MXT reported unit sales had increased more than 100% from the year prior.

In [a media release for investors discussing this news](#), CEO Durward explained that this result is a part of a trend that is continuing to push higher.

stockhouse editorials

Stockhouse.

"I believe this trend is due to increased certainty around both the US political situation going forward, Covid-19 vaccine availability, and a general trend toward cannabis legalization worldwide."



(Image via MedXtractor Corp.)



(Video via MedXtractor Corp. Click to play - https://www.youtube.com/watch?list=TLGGbR_ILqAeeGUxNzAyMjAyMQ&v=6u_a_sJlZ0&feature=emb_title)

What about investment?

While MXT has relied on extractor-based cash flow during SHAMAN's specification, proof-of-concept and testing phase, it expects that accelerated validated record collection will require additional resources. To this end, on February 17 a \$1.6 million Unit financing was announced. The Units are priced at \$0.20 - reflecting a market capitalization of around \$5.4 million, a very low valuation compared to its peers. Considering the increasing unit sales, positive operational cash flow, cash in the bank and no debt, MXT already looks like a good deal. While SHAMAN appears to hold great promise, it's in the beginning stage of development so CEO Durward was asked to comment about SHAMAN's potential. He responded: "Stock market fortunes are not based on what exists today, rather they are based on the "potential of tomorrow". While SHAMAN is in it's infancy, I believe it carries the potential to fundamentally change the way healthcare is managed tomorrow". With this in mind, it looks like an ideal time for investors to deepen their due diligence into this opportunity before it "grows away".

For more information on this Company, visit medextractor.com or for SHAMAN information, see <http://www.shaman-ai.com>

* [Canada Mental illness rates](#)

** [NCBI Misdiagnosis rates](#)

FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.